Media Advisory - Showcase and results announcement of SSHRC Storytellers Challenge to take place in Fredericton New Brunswick at Canada's largest science communications conference.
FREDERICTON, NB, June 12, 2025 /CNW/ - Join the Social Sciences and Humanities Research Council (SSHRC) at the University of New Brunswick, during the Science Writers and Communicators of Canada conference, for the SSHRC Storytellers Challenge showcase.
In this annual competition, now in its 12th year, SSHRC challenges postsecondary students to show Canadians, in up to three minutes or 300 words, how social sciences and humanities research is affecting our lives, our world and our future for the better. Before a panel of judges, 20 finalists will present their inspiring stories and demonstrate how SSHRC-funded research is making a difference in our world.
On Friday, June 13, SSHRC's Vice-President of Stakeholder Engagement and Advancement of Society, Tara Lapointe, will announce the winners, chosen from a pool of 161 submissions from students across Canada, at the Storytellers showcase.
Members of the media wishing to cover the event are asked to confirm their attendance in advance by emailing [email protected].
Contacts:
SOURCE Social Sciences and Humanities Research Council of Canada (SSHRCC)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
12 minutes ago
- Cision Canada
/R E P E A T --Media Advisory - Showcase and results announcement of SSHRC Storytellers Challenge to take place in Fredericton New Brunswick at Canada's largest science communications conference./
FREDERICTON, NB, June 12, 2025 /CNW/ - Join the Social Sciences and Humanities Research Council (SSHRC) at the University of New Brunswick, during the Science Writers and Communicators of Canada conference, for the SSHRC Storytellers Challenge showcase. In this annual competition, now in its 12th year, SSHRC challenges postsecondary students to show Canadians, in up to three minutes or 300 words, how social sciences and humanities research is affecting our lives, our world and our future for the better. Before a panel of judges, 20 finalists will present their inspiring stories and demonstrate how SSHRC-funded research is making a difference in our world. On Friday, June 13, SSHRC's Vice-President of Stakeholder Engagement and Advancement of Society, Tara Lapointe, will announce the winners, chosen from a pool of 161 submissions from students across Canada, at the Storytellers showcase. Members of the media wishing to cover the event are asked to confirm their attendance in advance by emailing [email protected]. Contacts: SOURCE Social Sciences and Humanities Research Council of Canada (SSHRCC)
Cision Canada
3 hours ago
- Cision Canada
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Cision Canada
18 hours ago
- Cision Canada
Toronto's AI Education Push Faces a Critical Test: Can It Be Inclusive?
TORONTO, June 12, 2025 /CNW/ - As artificial intelligence transforms industries, Toronto is emerging as a key player in preparing the next generation for a digital world. But a crucial question is now taking center stage: Who gets left behind? That question was front and centre at a high-profile panel during the 94th Congress of the Humanities and Social Sciences —Canada's largest academic gathering—held at George Brown College (GBC) from May 30 to June 6, 2025. The session brought together leaders in data science, innovation, and education to explore how Canada can build AI literacy without deepening existing inequalities. The discussion featured Debra Lam, Founding Executive Director of the Partnership for Inclusive Innovation, Heather Krause, data scientist and founder of We All Count, and Ryan Morrison, moderator and GBC Professor, English as a Second Language ESL. Morrison's current research concerns AI and its impacts on the language arts. He said the pace of change with this technology has been relentless. As he put it, "Every time our [research] group met, something new had happened." "So, I said, 'Whatever, I'll write a white paper.' And within two years, it was already irrelevant," he added. Closing the Innovation-Education Gap The panel emphasized that while AI's potential is enormous, the rollout of AI education must be equitable, deliberate, and community led. Slowing down and piloting thoughtfully is vital, urged Debra Lam. Such work must be done in collaboration between academia, government, and industry. "In academia, the big incentive is publication ... [while the] private sector, they need to provide some sort of return … [and for the] public sector, they need to report to their constituents," she said. "Once we understand what drives them and what their timelines are, then we can meet in the middle … and share the risk if we can do it together." Toronto, with its world-class education institutions, thriving tech ecosystem, and diverse communities, is uniquely positioned to lead this inclusive approach, panelists argued. Yet only if equity is taken into consideration from the outset, not treated as an afterthought. Lessons from Georgia: A Cautionary Tale Lam pointed to her home state of Georgia as an example of what can go wrong when policy outpaces preparation. In 2019, Georgia mandated computer science education for all high school students. But with little investment in training or infrastructure, biology teachers were suddenly tasked with teaching coding. The result: uneven quality and growing disparities between well-resourced and under-resourced schools. Speed alone isn't the goal, the panelists agreed. They argued the priority lies in quality, access, and long-term success in adopted AI in an educational setting. A Blueprint for Purpose-Driven AI Education Despite the challenges, panelists were optimistic. If educators, policymakers, and tech leaders can work together -- grounded in community needs and cultural humility -- Toronto could become a global model for inclusive, future-ready AI education. Not just quickly, but inclusively, and with purpose. George Brown College is helping to shape this future through its Applied A.I. Solutions Development postgraduate program (T431), designed to equip students with real-world AI skills while emphasizing ethics and inclusion. If you're interested in scheduling an interview with one of George Brown College's in-house experts, please reach out to Saron Fanel, External Communications Specialist [email protected]. About George Brown College Toronto's George Brown College is located on the traditional territory of the Mississaugas of the Credit First Nation and other Indigenous peoples. George Brown prepares innovative, adaptable graduates with the skills to thrive in a rapidly changing job market. With three campuses in the downtown core, the college blends theory with experiential learning, applied research, and entrepreneurship opportunities. George Brown offers 175 full-time programs and 182 continuing education certificates/designations across a wide variety of professions to more than 30,100 full-time students and receives more than 53,900 continuing education registrations annually. Students can earn certificates, diplomas, graduate certificates, apprenticeships, and degrees.
